“What we are trying to do more often is to ablate as much as we can,” said Shankar Siva, MBBS, PhD, FRANZCR, on pairing SABR with systemic therapy in RCC.
|Articles|June 4, 2009
- ONCOLOGY Vol 23 No 7
- Volume 23
- Issue 7
FDA Fast-Tracks Talactoferrin/Sunitinib for Renal Cell Carcinoma
Agennix announced that talactoferrin alfa has been granted Fast Track designation by the FDA for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent).
Advertisement
Agennix announced that talactoferrin alfa has been granted Fast Track designation by the FDA for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent). The Fast Track program is designed to expedite the review of investigational drugs for the treatment of patients with serious or life-threatening diseases where there is an unmet medical need.
Articles in this issue
over 17 years ago
Prophylactic Central Lymph Node Dissection: Continued Controversyover 17 years ago
Music Therapyover 17 years ago
Is There a Role for LHRH Antagonists in Prostate Cancer?over 17 years ago
The Role of LHRH Antagonists in the Treatment of Prostate CancerAdvertisement
Related to this article
Triplets did not beat pembrolizumab plus lenvatinib in frontline RCC, while belzutifan plus lenvatinib and perioperative pembrolizumab showed benefit.
Immune checkpoint inhibitors have reshaped treatment for extensive-stage small cell lung cancer, though their role in limited-stage disease remains uncertain.
Indocyanine green may be highly sensitive in the identification of ovarian cancer metastases, though with low specificity.
Advertisement
Advertisement
Trending on CancerNetwork
1
Iza-Bren Plus Pembrolizumab Shows Activity in Recurrent or Metastatic HNSCC
2
New ASTRO Guideline Backs Hypofractionated Radiation in Prostate Cancer
3
Pembrolizumab Plus Chemo Improves PFS in PD-L1+ HR+/HER2– Breast Cancer
4
A Pilot Trial of N-803: Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
5